Lunai Bioworks (STU:2Q5) Moat Score: 3/10 (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2Q5 Lunai Bioworks Inc STU:2Q5
26 GF Score
Price €8.37
! 6 Warning Signs
View Full Analysis

What is Lunai Bioworks Moat Score?

Lunai Bioworks STU:2Q5 26 Moat Score is 3 as of Jul. 29, 2026. GuruFocus rates STU:2Q5 with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 1,393 Biotechnology companies, Lunai Bioworks ranks better than 75.59% on this metric.

Lunai Bioworks has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Lunai Bioworks has No Moat: Lunai Bioworks Inc operates in a competitive biotech sector with limited market share and no significant network effects. The company lacks strong intellectual property or brand loyalty, and its cost advantages and regulatory barriers are insufficient to establish a durable moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Lunai Bioworks might have No Moat - Very weak/transient advantages.

Lunai Bioworks  (STU:2Q5) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Lunai Bioworks Moat Score Related Terms

STU:2Q5 vs BCLI, BIVI, XCUR: Moat Score Comparison

For the Biotechnology subindustry, Lunai Bioworks's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lunai Bioworks Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lunai Bioworks's Moat Score distribution charts can be found below:

* The bar in red indicates where Lunai Bioworks's Moat Score falls into.


STU:2Q5
26GF Score
Lunai Bioworks Inc STU:2Q5
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Lunai Bioworks (STU:2Q5) has a Moat Score of 3 as of Jul. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Lunai Bioworks ranks #340 out of 1393 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Lunai Bioworks' Moat Score too high?
Lunai Bioworks' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Lunai Bioworks' value of 3 is 50% above this industry median. Based on the distribution chart, Lunai Bioworks ranks #340 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lunai Bioworks has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Lunai Bioworks' Moat Score compare to BCLI and BIVI?
According to the Biotechnology industry distribution chart, Lunai Bioworks ranks #340 out of 1393 companies for Moat Score. This places Lunai Bioworks in the top 24% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Lunai Bioworks' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lunai Bioworks's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lunai Bioworks's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lunai Bioworks stock overvalued right now?
Lunai Bioworks (STU:2Q5) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Lunai Bioworks' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Lunai Bioworks (STU:2Q5), the current Moat Score is 3 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lunai Bioworks Business Description

Other Exchanges LNAI:USA
Address 2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
26GF Score

Get the complete analysis for STU:2Q5

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.37
Price